Page 2 - Emcure

Investors lap up shares of Emcure, Bansal Wire; bids cross Rs 1.25 trillion

The demand for both issuances reflects the positive sentiment among investors and could be a harbinger for more initial public offerings (IPOs) in the coming weeks, said industry players

Bain Capital-backed Emcure Pharma IPO fully subscribed on Day 1 of offer

The issue, with a price band of Rs 960 to Rs 1,008 per share, will be open for public subscription till July 5. The IPO comprises fresh issuance of equity shares worth Rs 800 crore

Namita Thapar-backed Emcure Pharma IPO opens: GMP, price, apply or not?

Emcure Pharmaceuticals initial public offering is set to open for subscription on Wednesday, July, 3, 2024

Street signs: Sensex, Nifty surge; Emcure IPO; Manufacturing funds gamble

Emcure Pharmaceuticals' shares are commanding a premium of over 25 per cent above their price band

Emcure Pharma seeks to raise Rs 1,952 cr through IPO, issue opens July 3

Fourth largest IPO of 2024; company will use the proceeds to repay debt and for general corporate purposes

Emcure Pharmaceuticals gets market regulator Sebi's approval for IPO

IPO comprises fresh issue of equity shares worth Rs 800 crore and OFS of 13.6 million equity shares by promoters

Emcure, Gennova settle legal dispute with US-based HDT Bio, sign agreement

Litigation before courts in the US and arbitral tribunal in London settled, two sides say

MNCs partner Indian firms to boost market reach in pharmaceutical sector

MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas

Sanofi India, Emcure Pharma announce exclusive distribution partnership

Collaboration aligns with Sanofi's growth strategy in India, named 'India for India', aims to accelerate growth across its pharmaceuticals, specialty care, consumer healthcare, and vaccines business

Emcure Pharmaceuticals refiles IPO papers to Sebi, trims issue size

The company had first submitted draft papers for its IPO in August 2021

Emcure Pharma plans $400-500 mn IPO in 2024; hires JP Morgan, Jefferies

Emcure, backed by private equity firm Bain Capital, has hired investment banks JP Morgan, Jefferies and Kotak for the IPO, and is targeting a valuation of about $3 billion

Gennova's mRNA vaccine in legal storm after HDT Bio Corp sues Emcure

The US firm HDT Bio Corp has alleged that Emcure 'willfully and maliciously' violated the Defend Trade Secrets Act and Washington's laws against trade secret theft

Emcure Pharma to launch oral Covid drug for emergency use in India

Emcure Pharmaceuticals Ltd announced that it has received Emergency Use Authorisation approval for launch of Molnupiravir, an investigational oral anti-viral drug, for the treatment of mild Covid-19.

Gennova's mRNA-based Covid vaccine gets nod for Phase 2/3 clinical trials

Gennova's mRNA-based Covid vaccine development programme was partly funded by the DBT under Ind CEPI in June 2020

Emcure strengthens board by including 4 new independent directors

Emcure Pharmaceuticals on Tuesday said it has strengthened its board with the inclusion of four new independent directors, including former Foreign Secretary Vijay Keshav Gokhale. The others who have joined the company's board are Shailesh Ayyangar, Hitesh Jain and Vidya Yeravdekar. Earlier this year, Berjis Desai had taken over as the chairman of Emcure Board. The company has had a long-standing tradition of appointing a Chairman from amongst its independent directors since 1997. "We are delighted to have highly accomplished industry stalwarts as part of our board. New members' combined experience and wider perspective from their respective fields, will play an instrumental role in strengthening our strategic operations to grow in domestic and international markets," Emcure Pharmaceuticals Managing Director & CEO Satish Mehta said in a statement. The drug firm aims to further augment its strengths as one of the fastest growing pharmaceutical companies in India with a global reach

Emcure launches generic breast cancer drug 40% cheaper than innovator's

Emcure plans to capture 25 per cent of the market for the drug as well as expand the market through this cheaper alternative to the innovator drug

2 ex-executives of Emcure's US arm accused of price fixing

Jeffrey Glazer and Jason Malek are also charged with rigging bids and price collusion

US FDA warns Emcure Pharma, cites repeated data fudging at plant

Regulator writes to the firm on 'significant violations' of manufacturing practices at the company' s Pune plant